Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.0166 | 0.0166 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0239 | 0.638 | 0.6985 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0614 | 0.0614 |
Onchocerca volvulus | Poor gastrulation protein homolog | 0.0046 | 0.0166 | 0.5 |
Loa Loa (eye worm) | metabotropic GABA-B receptor subtype 2 | 0.0073 | 0.1031 | 0.1031 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.0614 | 0.078 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0285 | 0.7874 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0073 | 0.1031 | 0.1031 |
Echinococcus multilocularis | metabotropic glutamate receptor 2 | 0.0239 | 0.638 | 0.6319 |
Loa Loa (eye worm) | glutamate receptor | 0.0285 | 0.7874 | 0.7874 |
Schistosoma mansoni | hypothetical protein | 0.0046 | 0.0166 | 0.0182 |
Brugia malayi | metabotropic GABA-B receptor subtype 2 | 0.0046 | 0.0166 | 0.0211 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0324 | 0.9135 | 1 |
Onchocerca volvulus | Metabotropic glutamate receptor homolog | 0.0046 | 0.0166 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0351 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.0614 | 0.078 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0139 | 0.3157 | 0.3456 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0258 | 0.7009 | 0.8901 |
Loa Loa (eye worm) | glutamate receptor | 0.0112 | 0.2292 | 0.2292 |
Loa Loa (eye worm) | hypothetical protein | 0.0351 | 1 | 1 |
Brugia malayi | metabotropic glutamate receptor type 2 | 0.0139 | 0.3157 | 0.401 |
Loa Loa (eye worm) | receptor family ligand binding region containing protein | 0.0073 | 0.1031 | 0.1031 |
Echinococcus granulosus | metabotropic glutamate receptor 2 | 0.0239 | 0.638 | 0.6319 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.0614 | 0.0614 |
Brugia malayi | Receptor family ligand binding region containing protein | 0.0073 | 0.1031 | 0.1309 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 6.3096 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.